News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Miravant (MRVT) Obtains $15 Million Convertible Line Of Credit


10/19/2005 5:12:57 PM

SANTA BARBARA, Calif.--(BUSINESS WIRE)--March 8, 2005--Miravant Medical Technologies (OTCBB:MRVT), a pharmaceutical development company specializing in PhotoPoint(R) photodynamic therapy (PDT), announced today that it has finalized a convertible debt line-of-credit agreement for up to $15.0 million with a long-standing Miravant investor. The funds will be available at the Company's discretion in increments of up to $1.0 million per month, with any unused monthly borrowings to be carried forward. The borrowings are convertible into shares of Common Stock based on a premium of 110% of the average monthly closing price of the month preceding each borrowing request. Additionally, we will issue a warrant to purchase one-quarter of a share of Common Stock for each convertible share of Common Stock issued. The exercise price of each warrant will also be equal to 110% of the average monthly closing price of the month preceding the borrowing request.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES